FRONT-BRAF study: first-line PD-1/PD-L1 inhibitors achieved median OS of 40.9 months vs 25.2 months with BRAF/MEK inhibitors in metastatic BRAF V600E+ #NSCLC 🚬 Greater benefit found in smokers & ages 70+ Authors: @DiFedericoMD, @Biagio_Ricciut, et al https://t.co/54AXyveClK

Dica – Imunoterapia em CPCNP com mutação de BRAF Neste MOC-Dicas, o Dr MarceloCorassa discute o impacto de #imunoterapia versus terapia-alvo no #CPNPC BRAF mutado, baseado em estudo apresentado na #ASCO25 #LCSM #lungcancer @MarceloCorassa @Ro_Mariano85 https://t.co/f8xfoh0kuy

New Oncology Journal Club JUST OUT! OncoAlert 🚨& @VJOncology proudly present @BiagioRicciutMD 🇺🇸🫁of @DanaFarber Discussing his paper just out on Lancet Oncology on First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated

Report @JTOonline on DLL3 expression in #EGFR NSCLC after #SCLC transformation. DLL3 positive in 11/12 patients. Two of these patients received tarlatamab (one with osimertinib) with clinical benefit. Need prospective data here! https://t.co/FmnOO32AYR

Our reconstructed individual patient data meta-analysis aiming to identify populations that may benefit from dual immune checkpoint blockade with CTLA-4 and PD-(L)1 inhibition has just been published in @TheLancetOncol https://t.co/yGesDIXyGA 1/6

The FRONT-BRAF study, investigating the optimal 1st-line treatment for patients w/ stage IV BRAF V600E-mut NSCLC, has just been published in @TheLancetOncol https://t.co/ijbh8g3iwk This is a global effort involving 17 major cancer centres across Italy, USA, France, & Brazil. 1/9

🚨 Excited to share our 2 new studies published today in @TheLancetOncol — one offering deeper insight into refining #ICI for PD-L1–negative & 🧬#STK11-mutant #NSCLC, and the other exploring #ICI vs 💊#BRAF/MEKi in #BRAF V600E #NSCLC. @OncoAlert @IASLC #LCSM. /W✨@DiFedericoMD✨

Proud to share our first TRACERx cancer study integrating epigenomics + genomics in NSCLC as co-drivers of tumor evolution. Led by not me but by the wonderful @NnennayaKanu, @F_gimenoval, @ccastignani6, @VanLooLab

Science goodness and humility in one person..not so common! @BRicciutiMD @ACortelliniMD

🫁 Dr @collin_blakely @UCSFCancer presents MRD analysis from NeoADAURA #WCLC25 🔹 Osimertinib & osimertinib+chemo improved MRD clearance & reduced MRD detection pre-surgery vs. chemo 🔹Pre-surgical MRD clearance & MRD not detected associated with MPR #LCSM #LungCancer @IASLC

Exciting #ARROS1 phase 1/2 trial results of #zidesamtinib in ROS+ mNSCLC #WCLC25 @alexdrilon 💠Active in heavily pretreated pts: ORR 44% after 1-4 prior ROS1 TKIs; 51% after 1 prior TKI (criz or entrect) 💠Responses after prior repotrectinib & taletrectinib; active against G2032R

Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2?

The new FLAURA2 OS data presented at #WCLC25 is exciting - nearly four years of median OS with osimertinib + chemotherapy is remarkable progress for our community! Alongside the MARIPOSA data, it's essential to remember -- this isn't about competition. There is no

FLAURA2 trial: Osi + CT improves PFS & OS (⬇️ 23% risk death) vs Osi alone in mEGFR NSCLC. Qx: -Intensification for all pts? Benefit in some subgroups only (Brain) -Chemo or ami for intensification?toxicity QoL, relevant for decisions -Cost -Is Osi alone no more valid? #WCLC2025

#HARMONi: #Ivonescimab + chemo vs chemo in EGFRm NSCLC post–3rd gen TKI - PFS: 6.8 vs 4.4 mo (HR 0.52, p<0.0001) - OS: 16.8 vs 14.0 mo (HR 0.79, p=0.057) Will we see tail of the curve? The role of IO remains to be further defined in EGFRm NSCLC. #wclc2025

Well. I think the first line discussion is over.

This is a REALLY important slide for clinic. The #1 question my patients ask: “How long do I need to stay on the pemetrexed with #FLAURA2?” In the combo arm, the average pemetrexed exposure for patients was 8.3 months; 50% of patients stopped due to side effects. #WCLC25 @IASLC

A 12 month delta. Nuff said.

Even though he was somehow mocking me, we are proud of our friend @BRicciutiMD, showing how @IASLC grants helped shaping his career at the young Investigator workshop #wclc2025 @RobertoFerrara_

MOC Cast - Dieta Divina Neste episódio, Dra Carolina Alves da Costa Silva, especialista em microbioma intestinal, está aqui para explicar como funciona a análise da composição da dieta dos pctes oncológicos @camillayamada @FabioSchutz78 @MarceloCorassa https://t.co/xQpqUwgCRh